tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating
PremiumRatingsKymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating
5d ago
Kymera Therapeutics: Promising KT-621 Progress and Strong Financial Position Justify Buy Rating
Premium
Ratings
Kymera Therapeutics: Promising KT-621 Progress and Strong Financial Position Justify Buy Rating
5d ago
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships
Premium
Company Announcements
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships
5d ago
Is KYMR a Buy, Before Earnings?
PremiumPre-EarningsIs KYMR a Buy, Before Earnings?
18d ago
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
Premium
The Fly
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
1M ago
Gilead estimates Q2 acquired IPR&D expenses of $61M
Premium
The Fly
Gilead estimates Q2 acquired IPR&D expenses of $61M
1M ago
Kymera Therapeutics price target raised to $54 from $51 at BofA
PremiumThe FlyKymera Therapeutics price target raised to $54 from $51 at BofA
2M ago
Kymera Therapeutics Announces Public Offering to Raise Funds
Premium
Company Announcements
Kymera Therapeutics Announces Public Offering to Raise Funds
2M ago
Kymera Therapeutics Holds Annual Shareholder Meeting
Premium
Company Announcements
Kymera Therapeutics Holds Annual Shareholder Meeting
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100